Sangamo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 26-10989). Following the bankruptcy filing, the company's common stock began trading on the OTCID Basic Market under the symbol "SGMOQ" on June 24, 2026. Additionally, the company terminated the engagement of Ernst & Young LLP as its independent registered public accounting firm on June 25, 2026. Sangamo Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for genetic diseases.
